cytori_8k03122008.htm

-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, FJqSW7vbBzXhaq5+sv/hlNjeVKDL633OTP8Y8dylGbjtoRNdiGll1V3peFTmI04a 3CWsPpeoYD8Edh6k9DSYLQ== 0001095981-08-000013.txt : 20080312 0001095981-08-000013.hdr.sgml : 20080312 20080312092702 ACCESSION NUMBER: 0001095981-08-000013 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20080312 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20080312 DATE AS OF CHANGE: 20080312 FILER: COMPANY DATA: COMPANY CONFORMED NAME: CYTORI THERAPEUTICS, INC. CENTRAL INDEX KEY: 0001095981 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 330827593 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-32501 FILM NUMBER: 08682438 BUSINESS ADDRESS: STREET 1: 3020 CALLAN ROAD CITY: SAN DIEGO STATE: CA ZIP: 92121 BUSINESS PHONE: 8584580900 MAIL ADDRESS: STREET 1: 3020 CALLAN ROAD CITY: SAN DIEGO STATE: CA ZIP: 92121 FORMER COMPANY: FORMER CONFORMED NAME: MACROPORE INC DATE OF NAME CHANGE: 20010320 8-K 1 cytori_8k03122008.htm CYTORI THERAPEUTICS FORM 8-K FILED 03-12-2008 cytori_8k03122008.htm

Delaware	000-32501	33-0827593
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(I.R.S. Employer Identification Number)

	CYTORI THERAPEUTICS, INC.

Date: March 12, 2008	By: /s/ Mark E. Saad
	Mark E. Saad
	Chief Financial Officer

	Three Months Ended December 31,						For the Years Ended December 31,
	2007			2006			2007			2006

Product revenues, related party	$	—		$	363,000		$	792,000		$	1,451,000

Cost of product revenues		—			293,000			422,000			1,634,000

Gross profit (loss)		—			70,000			370,000			(183,000	)

Development revenues:
Development, related party		—			5,222,000			5,158,000			5,905,000
Development		—			3,000			10,000			152,000
Research grants and other		25,000			7,000			89,000			419,000

		25,000			5,232,000			5,257,000			6,476,000
Operating expenses:
Research and development		5,438,000			5,228,000			20,020,000			21,977,000
Sales and marketing		995,000			471,000			2,673,000			2,055,000
General and administrative		4,408,000			2,542,000			14,184,000			12,547,000
Change in fair value of option liabilities		—			(917,000	)		100,000			(4,431,000	)

Total operating expenses		10,841,000			7,324,000			36,977,000			32,148,000

Operating loss		(10,816,000	)		(2,022,000	)		(31,350,000	)		(25,855,000	)

Other income (expense):
Gain on sale of assets		—			—			1,858,000			—
Interest income		181,000			170,000			1,028,000			708,000
Interest expense		(27,000	)		(41,000	)		(155,000	)		(199,000	)
Other expense, net		(8,000	)		(13,000	)		(46,000	)		(27,000	)
Equity loss from investment in joint venture		(9,000	)		(5,000	)		(7,000	)		(74,000	)

Total other income		137,000			111,000			2,678,000			408,000

Net loss		(10,679,000	)		(1,911,000	)		(28,672,000	)		(25,447,000	)

Other comprehensive income (loss) - unrealized holding income (loss)		—			35,000			(1,000	)		17,000

Comprehensive loss	$	(10,679,000	)	$	(1,876,000	)	$	(28,673,000	)	$	(25,430,000	)

Basic and diluted net loss per common share	$	(0.44	)	$	(0.10	)	$	(1.25	)	$	(1.53	)

Basic and diluted weighted average common shares		24,037,980			18,715,967			22,889,250			16,603,550